+

PE20010744A1 - USE OF (2S, 3S, 5R) -2- (3,5-DIFLUOROPHENYL) -3,5-DIMETHYL-2-MORPHOLINOL FOR THE TREATMENT OF OBESITY - Google Patents

USE OF (2S, 3S, 5R) -2- (3,5-DIFLUOROPHENYL) -3,5-DIMETHYL-2-MORPHOLINOL FOR THE TREATMENT OF OBESITY

Info

Publication number
PE20010744A1
PE20010744A1 PE2000001089A PE0010892000A PE20010744A1 PE 20010744 A1 PE20010744 A1 PE 20010744A1 PE 2000001089 A PE2000001089 A PE 2000001089A PE 0010892000 A PE0010892000 A PE 0010892000A PE 20010744 A1 PE20010744 A1 PE 20010744A1
Authority
PE
Peru
Prior art keywords
morpholinol
dimethyl
obesity
difluorophenyl
treatment
Prior art date
Application number
PE2000001089A
Other languages
Spanish (es)
Inventor
David Lee Musso
Jessica E Matthews
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9924275.2A external-priority patent/GB9924275D0/en
Priority claimed from GB0001861A external-priority patent/GB0001861D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20010744A1 publication Critical patent/PE20010744A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

SE REFIERE AL USO DE (2S,3S,5R)-2-(3,5-DIFLUOROFENIL)-3,5-DIMETIL-2-MORFOLINOL DE FORMULA I, PARA TRATAR LA OBESIDAD, SUPRIMIR EL APETITO, CAUSAR LA PERDIDA DE PESO, PREVENIR EL AUMENTO DE PESOREFERS TO THE USE OF (2S, 3S, 5R) -2- (3,5-DIFLUOROPHENIL) -3,5-DIMETHYL-2-MORPHOLINOL OF FORMULA I, TO TREAT OBESITY, TO SUPPRESS APPETITE, TO CAUSE WEIGHT LOSS , PREVENT WEIGHT GAIN

PE2000001089A 1999-10-13 2000-10-11 USE OF (2S, 3S, 5R) -2- (3,5-DIFLUOROPHENYL) -3,5-DIMETHYL-2-MORPHOLINOL FOR THE TREATMENT OF OBESITY PE20010744A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9924275.2A GB9924275D0 (en) 1999-10-13 1999-10-13 Method for the treatment of obesity
GB0001861A GB0001861D0 (en) 2000-01-28 2000-01-28 Method for the treatment of obesity

Publications (1)

Publication Number Publication Date
PE20010744A1 true PE20010744A1 (en) 2001-07-23

Family

ID=26243494

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000001089A PE20010744A1 (en) 1999-10-13 2000-10-11 USE OF (2S, 3S, 5R) -2- (3,5-DIFLUOROPHENYL) -3,5-DIMETHYL-2-MORPHOLINOL FOR THE TREATMENT OF OBESITY

Country Status (6)

Country Link
EP (1) EP1220673A2 (en)
JP (1) JP2003511410A (en)
AR (1) AR026022A1 (en)
AU (1) AU7750100A (en)
PE (1) PE20010744A1 (en)
WO (1) WO2001026641A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2318547C2 (en) 2001-08-08 2008-03-10 Кевин Р. ОРТОН Method and device for reducing weight using electric conductivity
EP3173082A1 (en) 2002-05-17 2017-05-31 Duke University Method for treating obesity
EP1617832B1 (en) 2003-04-29 2008-03-12 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
EP2292220A3 (en) 2005-11-22 2012-01-04 Orexigen Therapeutics, Inc. Composition and methods for increasing insulin sensitivity
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
MX343867B (en) 2006-11-09 2016-11-25 Orexigen Therapeutics Inc Methods for administering weight loss medications.
WO2009071678A2 (en) * 2007-12-05 2009-06-11 Biovitrum Ab (Publ) Morpholine derivatives as antiobesity agents
WO2009158114A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
JP2011522009A (en) * 2008-06-04 2011-07-28 アストラゼネカ アクチボラグ New compound VII
EP3659604A1 (en) 2010-01-11 2020-06-03 Nalpropion Pharmaceuticals, Inc. Methods of providing weight loss therapy in patients with major depression
KR20220042241A (en) 2012-06-06 2022-04-04 오렉시젠 세러퓨틱스 인크. Methods of treating overweight and obesity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8924528D0 (en) * 1989-10-31 1989-12-20 Wellcome Found Heterocyclic pharmaceutical compounds,preparation and use
JP2001524960A (en) * 1997-04-24 2001-12-04 メルク シヤープ エンド ドーム リミテツド Use of an NK-1 receptor antagonist to treat an eating disorder
AU1403899A (en) * 1997-11-14 1999-06-07 Glaxo Group Limited Method of treating addiction to nicotine products
EA002410B1 (en) * 1998-01-21 2002-04-25 Глаксо Груп Лимитед Pharmaceutically active morpholinol
MA26693A1 (en) * 1998-09-28 2004-12-20 Glaxo Group Ltd COMPOSITIONS FOR ORAL ADMINISTRATION

Also Published As

Publication number Publication date
WO2001026641A2 (en) 2001-04-19
JP2003511410A (en) 2003-03-25
AR026022A1 (en) 2002-12-26
AU7750100A (en) 2001-04-23
WO2001026641A3 (en) 2002-01-10
EP1220673A2 (en) 2002-07-10

Similar Documents

Publication Publication Date Title
MXPA04001037A (en) N-phenylpyrrole guanidine derivatives as melanocortin reception ligands.
NO20003233L (en) 4-hydroxyquinoline-3-carboxamides and hydrazides as antivirals
CY1111050T1 (en) PHOSPHONES, MONO-PHOSPHONAMIDES, BISPHOSPHONAMIDES FOR THE TREATMENT OF VIRUS DISEASES
ATE384058T1 (en) THIAZOLE DERIVATIVES
DE69830504D1 (en) ANTITROMOMBOTIC MEANS
BRPI0510177B8 (en) compound, pharmaceutical composition and use thereof
HK1080470B (en) Heterocyclic compounds
HK1088845A1 (en) Use of parthenolide derivatives as antileukemic and cytotoxic agents
BRPI0417684A (en) compound, pharmaceutical composition, and use of a compound
PT1200412E (en) IMIDAZOLE ANTI-PROLIFERATIVE AGENTS
ATE484508T1 (en) FURYL COMPOUNDS
ATE477256T1 (en) THIENYL COMPOUNDS
MXPA05007115A (en) Novel cb 1 receptor inverse agonists.
DE60121461D1 (en) CONDENSED PYRIDOINDOL DERIVATIVES
PE20010744A1 (en) USE OF (2S, 3S, 5R) -2- (3,5-DIFLUOROPHENYL) -3,5-DIMETHYL-2-MORPHOLINOL FOR THE TREATMENT OF OBESITY
PE20010541A1 (en) USE OF A BENZIMIDAZOLE COMPOSITION TO TREAT CANCER
AR032432A1 (en) ONCOLITICAL COMBINATIONS FOR CANCER TREATMENT
MY129310A (en) C-4 carbonate taxanes
DK1373220T3 (en) Benzimidazoles which are useful in the treatment of sexual dysfunction
BR0305708A (en) Benzimidazole derivatives for the treatment of sexual dysfunction
EA200100141A1 (en) THERAPEUTIC COMPOSITION ON THE BASIS OF ISOFLAVONOIDS FOR APPLICATION IN THE TREATMENT OF TUMORS BY CYTOTOXIC AGENTS
DE60112960D1 (en) CONDENSED PYRIDOINDOL DERIVATIVES
RU94045271A (en) Use of 2-phenyl-3-aroylbenzothiophenes for terner's syndrome inhibition
ATE235480T1 (en) CHALCON COUMARINE
EA200100140A1 (en) THERAPEUTIC COMPOSITION ON THE BASIS OF FLAVONOIDS FOR APPLICATION IN TREATMENT OF TUMORS BY CYTOTOXIC AGENTS

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载